Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression

British Journal of Cancer

Volumn 103, Issue 7, 2010, Pages 1008-1018

  Hao, J ^a,b   Chen, H ^a,b   Madigan, M C ^a   Cozzi, P J ^a,b   Beretov, J ^a,b   Xiao, W ^a,b   Delprado, W J ^c   Russell, P J ^a,d,e   Li, Y ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

^c DOUGLASS HANLY MOIR PATHOLOGY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

CD147; CD44v3 10; metastasis; monocarboxylate transporters; multidrug resistance; prostate cancer

Indexed keywords

CD147 ANTIGEN; CD44V ANTIGEN; CD44V3-10 ANTIGEN; DOCETAXEL; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 4; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG; ABCB1 PROTEIN, HUMAN; CD44 PROTEIN, HUMAN; HERMES ANTIGEN; MONOCARBOXYLATE TRANSPORTER; MULTIDRUG RESISTANCE PROTEIN; TAXOID; TUMOR MARKER;

ADULT; AGED; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TISSUE MICROARRAY; ANIMAL; DISEASE COURSE; DRUG RESISTANCE; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PROSTATIC NEOPLASMS; TUMOR CELL LINE; UPREGULATION;

ADULT; AGED; ANIMALS; ANTIGENS, CD147; ANTIGENS, CD44; CELL LINE, TUMOR; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; MONOCARBOXYLIC ACID TRANSPORTERS; NEOPLASM METASTASIS; P-GLYCOPROTEIN; PROSTATIC NEOPLASMS; TAXOIDS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; P-GLYCOPROTEINS;

EID: 77957234813     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605839     Document Type: Article

References (52)

1. Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang VY, Kohler SJ, Tropp J, Hurd RE, Yen YF, Nelson SJ, Vigneron DB, Kurhanewicz J (2008) Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res 68: 8607-8615
2. Auzenne E, Ghosh SC, Khodadadian M, Rivera B, Farquhar D, Price RE, Ravoori M, Kundra V, Freedman RS, Klostergaard J (2007) Hyaluronic acid-paclitaxel: antitumour efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 9: 479-486 (Pubitemid 46983450)
3. Chen CT, Gan Y, Au JL, Wientjes MG (1998) Androgen-dependent and -independent human prostate xenograft tumours as models for drug activity evaluation. Cancer Res 58: 2777-2783 (Pubitemid 28311908)
4. Colone M, Calcabrini A, Toccacieli L, Bozzuto G, Stringaro A, Gentile M, Cianfriglia M, Ciervo A, Caraglia M, Budillon A, Meo G, Arancia G, Molinari A (2008) The multidrug transporter P-glycoprotein: a mediator of melanoma invasion? J Invest Dermatol 128: 957-971 (Pubitemid 351374289)
5. Cozzi PJ, Wang J, Delprado W, Madigan MC, Fairy S, Russell PJ, Li Y (2006) Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Human Pathol 37: 1442-1451 (Pubitemid 44584322)
6. Dean NR, Newman JR, Helman EE, Zhang W, Safavy S, Weeks DM, Cunningham M, Snyder LA, Tang Y, Yan L, McNally LR, Buchsbaum DJ, Rosenthal EL (2009) Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clin Cancer Res 15: 4058-4065
7. De Marzo AM, Bradshaw C, Sauvageot J, Epstein JI, Miller GJ (1998) CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate 34: 162-168 (Pubitemid 28156605)
8. Deora AA, Philp N, Hu J, Bok D, Rodriguez-Boulan E (2005) Mechanisms regulating tissue-specific polarity of monocarboxylate transporters and their chaperone CD147 in kidney and retinal epithelia. Proc Natl Acad Sci USA 102: 16245-16250 (Pubitemid 41688899)
9. Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, Bassett WW, Anast JW, Li LC, Urakami S, Terashima M, Verma M, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R (2004) CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res 64: 5956-5962 (Pubitemid 39129391)
10. Gallagher SM, Castorino JJ, Wang D, Philp NJ (2007) Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res 67: 4182-4189 (Pubitemid 46815064)
11. Gao AC, Lou W, Sleeman JP, Isaacs JT (1998) Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. Cancer Res 58: 2350-2352 (Pubitemid 28252693)
12. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899
13. Germann UA (1996) P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A: 927-944 (Pubitemid 26191761)
14. Hao JL, Cozzi PJ, Khatri A, Power CA, Li Y (2010) CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer. Curr Cancer Drug Targ 10: 287-306
15. Harrison GM, Davies G, Martin TA, Mason MD, Jiang WG (2006) The influence of CD44v3-v10 on adhesion, invasion and MMP-14 expression in prostate cancer cells. Oncol Rep 15: 199-206
16. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249
17. Kallakury BV, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, Fisher HA, Kaufman R, Figge H, Ross JS (1996) Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumour grade and ploidy. Cancer 78: 1461-1469 (Pubitemid 26317867)
18. Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP (2000) CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J 19: 3896-3904 (Pubitemid 30608530)
19. Klein CA, Seidl S, Petat-Dutter K, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O, Wendler N, Passlick B, Huber RM, Schlimok G, Baeuerle PA, Riethmuller G (2002) Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol 20: 387-392 (Pubitemid 34286333)
20. Li QQ, Wang WJ, Xu JD, Cao XX, Chen Q, Yang JM, Xu ZD (2007) Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells. Cancer Sci 98: 1064-1069 (Pubitemid 46865392)
21. Madigan MC, Kingsley EA, Cozzi PJ, Delprado WJ, Russell PJ, Li Y (2008) The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. Cancer Immunol Immunother 57: 1367-1379
22. Marangoni E, Lecomte N, Durand L, de Pinieux G., Decaudin D, Chomienne C, Smadja-Joffe F, Poupon MF (2009) CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer 100: 918-922
23. Marieb EA, Zoltan-Jones A, Li R, Misra S, Ghatak S, Cao J, Zucker S, Toole BP (2004) Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res 64: 1229-1232 (Pubitemid 38235586)
24. Miletti-González KE, Chen S, Muthukumaran N, Saglimbeni GN, Wu X, Yang J, Apolito K, Shih WJ, Hait WN, Rodríguez-Rodríguez L (2005) The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 65: 6660-6667
25. Misra S, Ghatak S, Toole BP (2005) Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem 280: 20310-20315 (Pubitemid 40776728)
26. Nagabhusha M, Pretlow TG, Guo YJ, Amini SB, Pretlow TP, Sy MS (1996) Altered expression of CD44 human prostate cancer during progression. Am J Clin Pathol 106: 647-651 (Pubitemid 26392770)
27. Noordzij MA, van Steenbrugge GJ, Schroder FH, Van der Kwast TH (1999) Decreased expression of CD44 in metastatic prostate cancer. Int J Cancer 84: 478-483
28. Ohashi R, Takahashi F, Cui R, Yoshioka M, Gu T, Sasaki S, Tominaga S, Nishio K, Tanabe KK, Takahashi K (2007) Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell. Cancer Lett 252: 225-234 (Pubitemid 46809789)
29. Omara-Opyene AL, Qiu J, Shah GV, Iczkowski KA (2004) Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Lab Invest 84: 894-907 (Pubitemid 38833249)
30. Paradis V, Eschwège P, Loric S, Dumas F, Ba N, Beno?t G, Jardin A, Bedossa P (1998) De novo expression of CD44 in prostate carcinoma is correlated with systemic dissemination of prostate cancer. J Clin Pathol 51: 798-802 (Pubitemid 28530840)
31. Pinheiro C, Longatto-Filho A, Ferreira L, Pereira SM, Etlinger D, Moreira MA, Jube LF, Queiroz GS, Schmitt F, Baltazar F (2008a) Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. Int J Gynec Pathol 27: 568-574
32. Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, Rodrigues M, Alves VA, Schmitt F, Baltazar F (2008b) Increased expression of monocarboxylate transporters 1, 2 and 4 in colorectal carcinomas. Virchows Arch 452: 139-146
33. Pinheiro C, Longatto-Filho A, Simoes K, Jacob CE, Bresciani CJ, Zilberstein B, Cecconello I, Alves VA, Schmitt F, Baltazar F (2009) The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Eur J Cancer 45: 2418-2424
34. Platt VM, Szoka Jr FC (2008) Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 5: 474-486
35. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, Pantel K (2006) High incidence of EMMPRIN expression in human tumours. Int J Cancer 119: 1800-1810 (Pubitemid 44356836)
36. Rubin MA, Dunn R, Strawderman M, Pienta KJ (2002) Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26: 312-319 (Pubitemid 34184454)
37. Schneiderhan W, Scheler M, Holzmann KH, Marx M, Gschwend JE, Bucholz M, Gress TM, Seufferlein T, Adler G, Oswald F (2009) CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in-vivo and in-vitro models. Gut 58: 1391-1398
38. Slomiany MG, Grass GD, Robertson AD, Yang XY, Maria BL, Beeson C, Toole BP (2009) Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res 69: 1293-1301
39. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, Dewhirst MW (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumour cells in mice. J Clin Invest 118: 3930-3942
40. Su J, Chen X, Kanekura T (2009) A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down-regulating glycolysis. Cancer Lett 273: 140-147
41. Subramaniam V, Vincent IR, Gilakjan M, Jothy S (2007) Suppression of human colon cancer tumours in nude mice by siRNA CD44 gene therapy. Exp Mol Pathol 83: 332-340 (Pubitemid 350087029)
42. Surace C, Arpicco S, Dufaÿ-Wojcicki A, Marsaud V, Bouclier C, Clay D, Cattel L, Renoir JM, Fattal E (2009) Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cell. Mol Pharm 6: 1062-1073
43. Taetz S, Bochot A, Surace C, Arpicco S, Renoir JM, Schaefer UF, Marsaud V, Kerdine-Roemer S, Lehr CM, Fattal E (2009) Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells. Oligonucleotides 19: 103-116
44. Toole BP, Slomiany MG (2008) Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat 11: 110-121
45. Valdespino V, Tsagozis P, Pisa P (2007) Current perspectives in the treatment of advanced prostate cancer. Med Oncol 24: 273-286 (Pubitemid 350135948)
46. Van Brussel JP, Jan Van Steenbrugge G, Van Krimpen C, Bogdanowicz JF, Van Der Kwast TH, Schröder FH, Mickisch GH (2001) Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J Urol 165: 130-135
47. Wang L, Wu G, Yu L, Yuan J, Fang F, Zhai Z, Wang F, Wang H (2006) Inhibition of CD147 expression reduces tumour cell invasion in human prostate cancer cell line via RNA interference. Cancer Biol Ther 5: 608-614 (Pubitemid 44024714)
48. Xu J, Xu HY, Zhang Q, Song F, Jiang JL, Yang XM, Mi L, Wen N, Tian R, Wang L, Yao H, Feng Q, Zhang Y, Xing JL, Zhu P, Chen ZN (2007) HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol Cancer Res 5: 605-614 (Pubitemid 46985049)
49. Yadav AK, Mishra P, Agrawal GP (2008) An insight on hyaluronic acid in drug targeting and drug delivery. J Drug Target 16: 91-107 (Pubitemid 351266547)
50. Yan L, Zucker S, Toole BP (2005) Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 93: 199-204 (Pubitemid 40253722)
51. Yang JM, Xu Z, Wu H, Zhu H, Wu X, Hait WN (2003) Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 1: 420-427 (Pubitemid 36459252)
52. Zhong WD, Han ZD, He HC, Bi XC, Dai QS, Zhu G, Ye YK, Liang YX, Qin WJ, Zhang Z, Zeng GH, Chen ZN (2008) CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology 75: 230-236